BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share

BioAge Labs, Inc.

5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.
Underwriters have 30-day option to purchase up to 884,615 additional shares.
Proceeds to fund BGE-102, NLRP3, and APJ programs, plus working capital and debt reduction.
Goldman Sachs, Piper Sandler, and Citigroup are joint book-running managers.
Offering expected to close on January 23, 2026, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters
Value: $107.6 million
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

BioAge Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-019536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.